July 12th 2024
“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Genzyme Molecular Oncology Begins Kidney Cancer Vaccine Trial
December 1st 2002FRAMINGHAM, Massachusetts-Genzyme Molecular Oncology has launched a phase I/II vaccine trial in advanced kidney cancer. The vaccine is made by combining the patient’s own cancer cells with dendritic cells using an electrical fusion approach. Up to 20 patients will be enrolled at Beth Israel Deaconess Medical Center and the Dana-Farber Cancer Institute, Boston.
Monitoring Pregnancy Is Key After Wilms’ Treatment
November 1st 2002Women who received radiation therapy for Wilms’ Tumor are at increased risk of complications during pregnancy and, therefore, should be carefully assessed and monitored by their obstetricians. These conclusions were part of a National Wilms’
High-Dose Interleukin-2 in Metastatic Disease: Renal Cell Carcinoma and Melanoma
November 1st 2002Despite significant advances in the treatment of a variety of malignancies, highly effective therapies for most patients with metastatic renal cell carcinoma or metastatic melanoma are rare. Traditional oncologic treatment methods, such as
Current Status of Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma and Metastatic Melanoma
November 1st 2002Interleukin-2 (IL-2, Proleukin) is one of the most effective agents in the treatment of metastatic renal cell carcinoma and metastatic melanoma. High-dose IL-2 therapy produces overall response rates of 15% to 20%;
Current Clinical Trials of Flavopiridol
September 1st 2002Flavopiridol [2-(2-chlorophenyl 5 ,7-dihydroxy-8-[cis-(3-hydroxy-1-methyl-4-piperidinyl)-4H-1-benzopyran-4-one, hydrochloride] is a semisynthetic flavone with a novel structure compared with that of polyhydroxylated flavones, such as quercetin and genistein.[1] It is derived from rohitukine, an alkaloid isolated from the stem bark of Dysoxylum binectariferum, a plant indigenous to India.[2] Originally synthesized and supplied by Hoechst India Limited, flavopiridol is provided to the Division of Cancer Treatment and Diagnosis of the National Cancer Institute (NCI) by Aventis Pharmaceuticals, Inc.
Docetaxel in the Management of Advanced or Metastatic Urothelial Tract Cancer
June 1st 2002Phase II studies of single-agent docetaxel (Taxotere) yielded promising results in advanced or metastatic transitional cell carcinoma (TCC) of the urothelium. Antitumor responses have been demonstrated in previously treated and chemotherapy-naive TCC patients, as well as in a subgroup of patients with renal impairment unable to receive traditional cisplatin-based regimens.
Radiofrequency Ablation Proving Effective in Small Renal Cell Tumors
November 1st 2001ANAHEIM, California-Percutaneous radiofrequency ablation, which is FDA-approved for treating liver and soft tissue neoplasms, may also be useful in renal cell carcinoma, according to several reports from the American Urological Association annual meeting.
High-Dose IL-2 Is Standard in Advanced Renal Cell Cancer
October 10th 2001SAN FRANCISCO-Trials employing outpatient use of subcutaneous (SC) interleukin-2 (IL-2, Proleukin) in lower doses suggest that the overall response rate in metastatic renal cell carcinoma is adversely affected by the decrease in dose or the subcutaneous route of administration.
High-Dose IL-2 Associated With Improved Response in Renal Cell Carcinoma Patients
September 1st 2001Preliminary results of a phase III trial of high-dose recombinant human interleukin-2 (IL-2, Proleu kin) demonstrated increased response rates with a longer median duration, compared to outpatient subcutaneous IL-2 in conjunction with
Current Clinical Trials of Epothilone B Analog (BMS-247550)
September 1st 2001BMS-247550 is a methyl, semi-synthetic analog of the natural product epothilone B. Provided to the National Cancer Institute (NCI) by Bristol-Myers Squibb, BMS-247550 was chosen for clinical development because it demonstrated
Epidermal Growth Factor Receptor Inhibitors in Clinical Trials
June 1st 2001With the understanding of the mechanism of malignant transformation has come the knowledge that oncogene products are frequently growth factors, growth factor receptors, or elements of growth factor signal-transduction pathways. Overexpression
Thalidomide for Recurrent Renal-Cell Cancer in a 40-Year-Old Man
December 1st 2000A pilot study was performed at The University of Texas M. D. Anderson Cancer Center to determine the feasibility of using thalidomide in a population of renal-cell carcinoma patients who had progressive disease despite chemotherapy and immunotherapy. Metastatic renal-cell carcinoma patients with adequate oral function were entered onto a study after signing an internal review board-approved informed consent. There were no exclusion criteria for prior therapy. Nineteen previously treated patients and one untreated patient with progressive renal-cell carcinoma received oral thalidomide as a single agent. The starting dose was 200 mg and the dose was increased by 100 to 200 mg every week until it reached 1,200 mg/d. Response was assessed on the basis of a radiographic reduction of the metastatic sites involved. A case report describing one of the patients involved in the pilot trial is included. [ONCOLOGY 14(Suppl 13):33-36, 2000]
Allogeneic Stem Cell Transplant Effective in Kidney Cancer
November 1st 2000BETHESDA, Md-In a pilot study, 10 of 19 patients with advanced renal cell cancer had a response to nonmye-loablative allogeneic peripheral blood stem cell transplantation, reported Richard Childs, MD, of the National Heart, Lung, and Blood Institute.
Thalidomide Treatment of Metastatic Renal-Cell Carcinoma
November 1st 2000Thalidomide (Thalomid) has antiangiogenic and immunomodulatory properties with activity in myeloma and other tumors. We treated 15 patients with advanced progressive metastatic renal-cell cancer with escalating divided daily doses of thalidomide
Nephrectomy Before Interferon Improves Survival in Patients with Renal Cancer
July 1st 2000MAYWOOD, Ill-Removing the cancerous kidney before administering interferon alfa-2b (Intron A) improves survival in advanced renal cancer, according to results of Southwest Oncology Group (SWOG) Trial 8949. The role of interferon treatment, however, remains controversial.
Nephrectomy Ups Survival in Advanced Kidney Cancer
July 1st 2000ASCO-Cytoreductive nephrectomy prior to interferon-alfa-2b (Intron A) therapy increased survival by 50% in patients with previously untreated metastatic renal cell cancer, compared with interferon alone, Robert Flanigan, MD, reported at the plenary session of the 36th Annual Meeting of the American Society of Clinical Oncology in New Orleans.
Fluorescent Marker Permits Clean Partial Nephrectomy
June 1st 2000ATLANTA-A fluorescent marker given 4 hours before surgery lights up renal cell carcinoma cells and eliminates the need for frozen sections to guarantee clean margins during kidney-preserving tumor resection, German researchers reported in a poster presented at the 95th Annual Meeting of the American Urological Association (AUA).
New Anticancer Agent With Minimal Side Effects Has Unique Mechanism of Action
February 1st 2000An ongoing phase I clinical trial shows that a new anticancer agent, CCI-779, is well-tolerated and may have antitumor activity. CCI-779 is a derivative of rapamycin, an immunosuppressive agent. Results of the study were presented at the
Management of Renal Cell Carcinoma
January 1st 2000Drs. Wolchok and Motzer provide a succinct, timely review of the diagnosis and management of renal carcinoma. The article leads us to ask a number of questions: What factors account for the major increase in the incidence of renal carcinoma? How has surgical management evolved with the advent of newer operative techniques? What role, if any, does chemotherapy play in the treatment of this disease? What is the current status of and future outlook for immunotherapeutic approaches?
Anti-VEGF MoAb Promising in Phase II Renal Cancer Study
November 1st 1999BETHESDA, Md-Some kidney cancer patients in an ongoing phase II trial of an experimental antiangiogenesis monoclonal antibody have shown improvement. The randomized, three-arm study by National Cancer Institute researchers compares two different doses of the drug against a placebo.
Current Management of Unusual Genitourinary Cancers: Part II
November 1st 1999Often overshadowed by more common genitourinary cancers, such as prostate, testicular, and kidney cancers, penile and urethral cancers nonetheless represent difficult treatment challenges for the clinician. The management of these cancers is slowly evolving. In the past, surgery, often extensive, was the treatment of choice. Recently, however, radiation and chemotherapy have begun to play larger roles as initial therapies, with surgery being reserved for salvage. With these modalities in their treatment armamentarium, oncologists may now be able to spare patients some of the physical and psychological sequelae that often follow surgical intervention without compromising local control and survival. Part 1 of this two-part article, published in last month’s issue, dealt with cancer of the penis. This second part focuses on cancer of the urethra in both females and males. [ONCOLOGY 13(11):1511-1520, 1999]
Trichloroethylene Exposure Linked to Genetic Changes in Patients With Kidney Cancer
October 1st 1999Many patients with kidney cancer who had been exposed to high levels of trichloroethylene have a unique pattern of genetic mutations within their cancerous cells. These findings were reported by Hiltrud Brauch, PhD, of the University of Hamburg,
Immune Response Key to Spontaneous Renal Cancer Regressions?
October 1st 1999WASHINGTON-“The possibility of spontaneous regression suggests that immunotherapy is a valid route to pursue in kidney cancer research,” said Ronald M. Bukowski, MD, director of the experimental therapeutics program at the Cleveland Clinic Cancer Center.
Twice Weekly IL-12 Shows Promise in Kidney Cancer
September 1st 1999WASHINGTON-“Enough evidence has accumulated to suggest that interleukin-12 [IL-12] deserves continued study in kidney cancer and other malignancies, even though it has had a difficult track record so far,” Janice P. Dutcher, MD, said at the 1999 Kidney Cancer Association Annual Convention. Dr. Dutcher is associate director for clinical affairs, Our Lady of Mercy Cancer Center/New York Medical College.
Monoclonal Antibodies May Be Used to Treat Kidney Cancer
September 1st 1999WASHINGTON-Monoclonal antibodies are the basis of many diagnostic tests, but now are catching on as therapy as well, said Neil Bander, MD, surgical director, Urologic Oncology Program, Cornell University and New York Presbyterian Hospital, New York. “This particular type of approach has now been validated clinically and is being used to treat patients with various types of cancer,” Dr. Bander said at the Kidney Cancer Association Annual Convention.